Intuitive Surgical, Inc. $ISRG Shares Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 94,113 shares of the medical equipment provider’s stock after acquiring an additional 8,725 shares during the period. Rakuten Investment Management Inc.’s holdings in Intuitive Surgical were worth $38,791,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Beaumont Financial Advisors LLC lifted its position in Intuitive Surgical by 3.8% during the 3rd quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 23 shares during the period. Hughes Financial Services LLC grew its stake in shares of Intuitive Surgical by 40.7% in the 3rd quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 24 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in shares of Intuitive Surgical by 1.0% in the first quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after purchasing an additional 25 shares during the period. Blue Fin Capital Inc. increased its holdings in shares of Intuitive Surgical by 0.5% in the first quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after purchasing an additional 25 shares during the period. Finally, Red Spruce Capital LLC increased its holdings in shares of Intuitive Surgical by 4.1% in the second quarter. Red Spruce Capital LLC now owns 640 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 25 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Up 0.9%

NASDAQ ISRG opened at $440.75 on Wednesday. The stock has a market capitalization of $152.78 billion, a price-to-earnings ratio of 53.30, a PEG ratio of 3.01 and a beta of 1.45. The business’s 50 day moving average is $404.05 and its two-hundred day moving average is $432.90. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The business had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same period last year, the firm earned $2.40 EPS. The company’s quarterly revenue was up 21.7% compared to the same quarter last year. Equities analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, Director Craig Barratt sold 1,150 shares of the stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total value of $510,370.00. Following the completion of the transaction, the director owned 1,150 shares in the company, valued at approximately $510,370. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the director directly owned 251 shares of the company’s stock, valued at approximately $95,129. This trade represents a 61.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 38,778 shares of company stock valued at $16,814,967 over the last three months. 0.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on ISRG. Citigroup cut their price target on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Robert W. Baird boosted their price objective on shares of Intuitive Surgical from $513.00 to $550.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Piper Sandler restated an “overweight” rating on shares of Intuitive Surgical in a research report on Friday, August 21st. TD Cowen restated a “buy” rating and issued a $485.00 target price on shares of Intuitive Surgical in a research note on Monday, October 19th. Finally, Mizuho lowered their target price on shares of Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating on the stock in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $493.54.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.